ArticleVirology journal2020
The recombinant pseudorabies virus expressing African swine fever virus CD2v protein is safe and effective in mice.
Article in Virology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Construction and Immunogenicity of a Recombinant Pseudorabies Virus Expressing the Major Neutralizing Epitopes A and D of Transmissible Gastroenteritis Virus Spike Protein.Veterinary sciences · 2026Article
- Combinatorial genome engineering of pseudorabies virus Bartha by developing a reverse genetic system based on three overlapping genomic segments.Journal of advanced research · 2026Article
- A quantum dots dual immunochromatography strip for differential detection of high and low virulence ASFV antibodies.Microbiology spectrum · 2026Article
- Optimizing encephalomyocarditis virus VP1 protein assembly on pseudorabies virus envelope via US9 protein anchoring.Virulence · 2025Article
- Development and efficacy of a novel mRNA cocktail for the delivery of African swine fever virus antigens and induction of immune responses.Microbiology spectrum · 2025Article
- Progress in African Swine Fever Vector Vaccine Development.International journal of molecular sciences · 2025Review
- Construction and Evaluation of Quadruple-Gene-Deleted Pseudorabies Virus Platforms for ASFV Antigen Delivery.Transboundary and emerging diseases · 2025Article
- Construction of and evaluation of the immune response to two recombinant pseudorabies viruses expressing the B119L and EP364R proteins of African swine fever virus.Archives of virology · 2024Article
- Development of novel monoclonal antibodies for blocking NF-κB activation induced by CD2v protein in African swine fever virus.Frontiers in immunology · 2024Article
- Generation and Characterization of Recombinant Pseudorabies Virus Delivering African Swine Fever VirusInternational journal of molecular sciences · 2023Article
- The CD2v protein of African swine fever virus inhibits macrophage migration and inflammatory cytokines expression by downregulating EGR1 expression through dampening ERK1/2 activity.Veterinary research · 2023Article
- An Intracellular Epitope of ASFV CD2v Protein Elicits Humoral and Cellular Immune Responses.Animals : an open access journal from MDPI · 2023Article
- Recombinant Pseudorabies Virus Usage in Vaccine Development against Swine Infectious Disease.Viruses · 2023Review
- An easy method to generate recombinant pseudorabies virus expressing the capsid protein of Porcine circovirus type 2d.Frontiers in microbiology · 2023Article
- Vaccines for African swine fever: an update.Frontiers in microbiology · 2023Review
- Article
- Comprehensive evaluation of the safety and immunogenicity of a gene-deleted variant pseudorabies virus attenuated vaccine.Veterinary research · 2022Article
- Review
- Review
- The recombinant pseudorabies virus expressing porcine deltacoronavirus spike protein is safe and effective for mice.BMC veterinary research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAfrican swine fever (ASF) leads to high mortality in domestic pigs and wild boar and is caused by the African swine fever virus (ASFV). Currently, no vaccine is commercially available for prevention, and the epidemic is still spreading. Here, we constructed a recombinant pseudorabies virus (PRV) (PRV-ΔgE/ΔgI/ΔTK-(CD2v)) that expresses the CD2v protein of ASFV and evaluated its effectiveness and safety as a vaccine candidate in mice.
methodsA homologous recombination fragment containing ASFV CD2v was synthesized and co-transfected into HEK 293 T cells, a knockout vector targeting the PRV TK gene. The transfected cells were infected with PRV-ΔgE/ΔgI, and the recombinant strain (PRV-ΔgE/ΔgI/ΔTK-(CD2v)) was obtained by plaque purification in Vero cells. The expression of ASFV CD2v in the recombinant virus was confirmed by sequencing, Western blotting, and immunofluorescence analysis, and the genetic stability was tested in Vero cells over 20 passages. The virulence, immunogenicity and protective ability of the recombinant virus were further tested in a mouse model.
resultsThe PRV-ΔgE/ΔgI/ΔTK-(CD2v) recombinant strain is stable in Vero cells, and the processing of CD2v does not depend on ASFV infection. The vaccination of PRV-ΔgE/ΔgI/ΔTK-(CD2v) causes neither pruritus, not a systemic infection and inflammation (with the high expression of interleukin-6 (IL6)). Besides, the virus vaccination can produce anti-CD2v specific antibody and activate a specific cellular immune response, and 100% protect mice from the challenge of the virulent strain (PRV-Fa). The detoxification occurs much earlier upon the recombinant virus vaccination and the amount of detoxification is much lower as well.
conclusionsThe PRV-ΔgE/ΔgI/ΔTK-(CD2v) recombinant strain has strong immunogenicity, is safe and effective, and maybe a potential vaccine candidate for the prevention of ASF and Pseudorabies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.